Financings in Brief: Gynecare
This article was originally published in The Gray Sheet
Gynecare: Expecting net proceeds of $24.9 mil. from an initial public offering of 2.3 mil. common shares. Gynecare announced Oct. 10 that it had filed a registration statement with SEC for the offering, which will be managed by UBS Securities, Hambrecht & Quist, and Volpe, Welty & Co. The proceeds, based on a projected offering price of $12 per share, will be used to "fund clinical trials, research and development, expansion of manufacturing operations, working capital and general corporate expenses," the firm says.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.